KBC Group NV increased its position in Enzo Biochem, Inc. (NYSE:ENZ) by 128.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,048 shares of the medical research company’s stock after purchasing an additional 9,598 shares during the quarter. KBC Group NV’s holdings in Enzo Biochem were worth $57,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in ENZ. BNP Paribas Arbitrage SA increased its position in Enzo Biochem by 1,298.2% in the first quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the medical research company’s stock worth $25,000 after purchasing an additional 8,581 shares during the period. Corient Capital Partners LLC acquired a new position in shares of Enzo Biochem during the 1st quarter worth about $31,000. SG Americas Securities LLC acquired a new position in shares of Enzo Biochem during the 1st quarter worth about $36,000. Bank of America Corp DE grew its position in shares of Enzo Biochem by 151.7% during the 4th quarter. Bank of America Corp DE now owns 67,911 shares of the medical research company’s stock worth $188,000 after buying an additional 40,929 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Enzo Biochem by 111.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 77,313 shares of the medical research company’s stock worth $211,000 after buying an additional 40,741 shares during the period. Hedge funds and other institutional investors own 66.99% of the company’s stock.
Separately, TheStreet upgraded Enzo Biochem from a “d” rating to a “c-” rating in a report on Tuesday, July 2nd.
NYSE ENZ traded down $0.06 during trading on Tuesday, hitting $3.73. The stock had a trading volume of 1,600 shares, compared to its average volume of 245,130. The company has a 50-day moving average price of $3.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.12 and a current ratio of 5.61. Enzo Biochem, Inc. has a 12 month low of $2.32 and a 12 month high of $5.00.
Enzo Biochem (NYSE:ENZ) last released its earnings results on Monday, June 10th. The medical research company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The firm had revenue of $19.66 million for the quarter. Enzo Biochem had a negative return on equity of 34.02% and a net margin of 2.49%.
About Enzo Biochem
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Featured Story: Beige Book
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.